Biological impediments to monoclonal antibody-based cancer immunotherapy

Molecular Cancer Therapeutics

Volumn 3, Issue 11, 2004, Pages 1493-1501

  Christiansen, Jason ^a   Rajasekaran, Ayyappan K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIIDIOTYPIC ANTIBODY; ANTINEOPLASTIC AGENT; BRADYKININ; CALICHEAMICIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DACLIZUMAB; DOXORUBICIN; EDETIC ACID; EDRECOLOMAB; EPRATUZUMAB; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; HISTAMINE; IBRITUMOMAB TIUXETAN; INTERLEUKIN 1BETA; LEUKOTRIENE B4; MICROSOMAL AMINOPEPTIDASE; MONOCLONAL ANTIBODY; PHYSALAEMIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; UVOMORULIN; VASOACTIVE AGENT;

ANTIGEN EXPRESSION; ANTIGENICITY; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CYTOTOXICITY; DISEASE MODEL; DOSE RESPONSE; DRUG APPROVAL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; EPITHELIUM; FOOD AND DRUG ADMINISTRATION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; METASTASIS; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT; SOLID TUMOR; STROMA; TARGET CELL; TISSUE PRESSURE; TUMOR CELL; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ENDOTHELIAL CELLS; EPITHELIAL CELLS; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 9444260479     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (109)

1. Glennie MJ, Johnson PW. Clinical trials of antibody therapy. Immunol Today 2000;21:403-10.
2. Von Mehren M, Adams GP, Weiner LM. Monoclonal antibody therapy for cancer. Annu Rev Med 2003;54:343-69.
3. Dillman RO. Monoclonal antibody therapy for lymphoma: an update. Cancer Pract 2001;9:71-80.
4. Countouriotis A, Moore TB, Sakamoto KM. Cell surface antigen and molecular targeting in the treatment of hematologic malignancies. Stem Cells 2002;20:215-29.
5. Pressman D, Korngold L. The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies. Cancer 1953;6:619-23.
6. Burnet FM. Immunological aspects of malignant disease. Lancet 1967; 1:1171-4.
7. Krzeslak A, Pomorski L, Gaj Z, Lipinska A. Differences in glycosylation of intracellular proteins between benign and malignant thyroid neoplasms. Cancer Lett 2003;196:101-7.
8. Mehl AM, Fischer N, Rowe M, et al. Isolation and analysis of two strongly transforming isoforms of the Epstein-Barr-Virus (EBV)-encoded latent membrane protein-1 (LMP1) from a single Hodgkin's lymphoma. Int J Cancer 1998;76:194-200.
9. Clark SS, McLaughlin J, Timmons M, et al. Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science 1988;239:775-7.
10. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244: 707-12.
11. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
12. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-5.
13. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998;52:637-40.
14. Wright GL Jr, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996;48:326-34.
15. Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998;83:2259-69.
16. McDevitt MR, Barendswaard E, Ma D, et al. An α-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res 2000;60:6095-100.
17. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003; 30:667-76.
18. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 2003;44: 610-7.
19. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17: 2639-48.
20. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-44.
21. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002;94:1593-611.
22. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
23. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999;59:1236-43.
24. Murray JL, Macey DJ, Grant EJ, et al. Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following α-interferon treatment. Cancer Res 1995; 55:5925s-8s.
25. Greiner JW, Guadagni F, Goldstein D, et al. Intraperitoneal administration of interferon-γ to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J Clin Oncol 1992;10:735-46.
26. Macey DJ, Grant EJ, Kasi L, et al. Effect of recombinant α-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial. Clin Cancer Res 1997;3:1547-55.
27. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7.
28. Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982;306: 517-22.
29. Sakahara H, Saga T, Onodera H, Yao Z, Nakamoto Y, Zhang M, et al. Anti-murine antibody response to mouse monoclonal antibodies in cancer patients. Jpn J Cancer Res 1997;88:895-9.
30. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother 1994;15:42-52.
31. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1:118-29.
32. Little M, Kipriyanov SM, Le Gall F, Moldenhauer G. Of mice and men: hybridoma and recombinant antibodies. Immunol Today 2000;21: 364-70.
33. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984;81:6851-5.
34. Boulianne GL, Hozumi N, Shulman MJ. Production of functional chimaeric mouse/human antibody. Nature 1984;312:643-6.
35. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986;321:522-5.
36. Hoogenboom HR, Chames P. Natural and designer binding sites made by phage display technology. Immunol Today 2000;21:371-8.
37. Fishwild DM, O'Donnell SL, Bengoechea T, Hudson DV, Harding F, Bernhard SL, et al. High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 1996;14:845-51.
38. Mendez MJ, Green LL, Corvalan JR, Jia XC, Maynard-Currie CE, Yang XD, et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet 1997;15: 146-56.
39. Green LL. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods 1999;231:11-23.
40. Manshouri T, Do KA, Wang X, Giles FJ, O'Brien SM, Saffer H, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003;101: 2507-13.
41. Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998;10:548-51.
42. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33.
43. Salisbury JR, Rapson NT, Codd JD, Rogers MV, Nethersell AB. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. J Clin Pathol 1994;47:313-7.
44. Dyer MJ. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol 1999;26:52-7.
45. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61.
46. Pawson R, Dyer MJ, Barge R, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997;15:2667-72.
47. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res 1984;8:521-34.
48. Andrews RG, Singer JW, Bernstein ID. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J Exp Med 1989;169:1721-31.
49. Jurcic JG, DeBlasio T, Dumont L, Yao TJ, Scheinberg DA. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res 2000;6: 372-80.
50. Sievers EL, Linenberger M. Mylotarg: antibody-targeted chemotherapy comes of age. Curr Opin Oncol 2001;13:522-7.
51. Leyland-Jones B. Trastuzumab: hopes and realities. Lancet Oncol 2002;3:137-44.
52. Riethmuller G, Schneider-Gadicke E, Schlimok G, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 1994;343:1177-83.
53. Riethmuller G, Holz E, Schlimok G, et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998;16:1788-94.
54. Mellstedt H, Frodin JE, Masucci G, et al. The therapeutic use of monoclonal antibodies in colorectal carcinoma. Semin Oncol 1991;18: 462-77.
55. Khawli LA, Miller GK, Epstein AL. Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors. Cancer 1994;73:824-31.
56. Goldenberg DM. Targeting of cancer with radiolabeled antibodies. Prospects for imaging and therapy. Arch Pathol Lab Med 1988; 112:580-7.
57. Epenetos AA, Snook D, Durbin H, Johnson PM, Taylor-Papadimitriou J. Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res 1986;46:3183-91.
58. Cooke SP, Pedley RB, Boden R, Begent RH, Chester KA. In vivo tumor delivery of a recombinant single chain Fv:tumor necrosis factor-α fusion [correction of factor: a fusion] protein. Bioconjug Chem 2002;13:7-15.
59. Azemar M, Djahansouzi S, Jager E, et al. Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Breast Cancer Res Treat 2003;82:155-64.
60. Eggermont AM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996; 14:2653-65.
61. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon γ: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996;14: 479-89.
62. Noorda EM, Vrouenraets BC, Nieweg OE, Van Coevorden F, Van Slooten GW, Kroon BB. Isolated limb perfusion with tumor necrosis factor-α and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Cancer 2003;98:1483-90.
63. Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF-α in cancer. Curr Opin Immunol 1998;10:573-80.
64. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002;110:475-82.
65. Folli S, Pelegrin A, Chalandon Y, Yao X, Buchegger F, Lienard D, et al. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer 1993;53:829-36.
66. LeBerthon B, Khawli LA, Alauddin M, et al. Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate. Cancer Res 1991;51:2694-8.
67. Hannigan TW, Begent RH, Allen-Mersh TG. Histamine, leukotriene C4 and interleukin-2 increase antibody uptake into a human carcinoma xenograft model. Br J Cancer 1991;64:872-4.
68. Thakur ML, DeFulvio J, Tong J, John E, McDevitt MR, Damjanov I. Evaluation of biological response modifiers in the enhancement of tumor uptake of technetium-99m labeled macromolecules. A preliminary report. J Immunol Methods 1992;152:209-16.
69. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000; 18:1185-90.
70. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999;5:2674-81.
71. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997;57:3629-34.
72. McIntosh DP, Tan XY, Oh P, Schnitzer JE. Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc Natl Acad Sci USA 2002;99:1996-2001.
73. Au JL, Jang SH, Zheng J, et al. Determinants of drug delivery and transport to solid tumors. J Control Release 2001;74:31-46.
74. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 1990;9:253-66.
75. Durand RE. Distribution and activity of antineoplastic drugs in a tumor model. J Natl Cancer Inst 1989;81:146-52.
76. Erlanson M, Daniel-Szolgay E, Carlsson J. Relations between the penetration, binding and average concentration of cytostatic drugs in human tumour spheroids. Cancer Chemother Pharmacol 1992;29:343-53.
77. Damsky CH, Richa J, Solter D, Knudsen K, Buck CA. Identification and purification of a cell surface glycoprotein mediating intercellular adhesion in embryonic and adult tissue. Cell 1983;34:455-66.
78. Green SK, Frankel A, Kerbel RS. Adhesion-dependent multicellular drug resistance. Anticancer Drug Des 1999;14:153-68.
79. Damiano JS, Hazlehurst LA, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and γ-irradiation. Leukemia 2001;15:1232-9.
80. St Croix B, Sheehan C, Rak JW, Florenes VA, Slingerland JM, Kerbel RS. E-cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J Cell Biol 1998;142:557-71.
81. Green SK, Karlsson MC, Ravetch JV, Kerbel RS. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer. Cancer Res 2002;62: 6891-900.
82. Sasaki H, Igarashi Y, Nagano T, Nishida K, Nakamura J. Different effects of absorption promoters on corneal and conjunctival penetration of ophthalmic β-blockers. Pharm Res 1995;12:1146-50.
83. Morita T, Yamamoto A, Hashida M, Sezaki H. Effects of various absorption promoters on pulmonary absorption of drugs with different molecular weights. Biol Pharm Bull 1993;16:259-62.
84. Murakami T, Misaki M, Kojima Y, et al. Effect of absorption promoters on subcutaneous absorption of human epidermal growth factor in rats. J Pharm Sci 1993;82:236-9.
85. Duvillard C, Ponelle T, Chapusot C, Piard F, Romanet P, Chauffert B. EDTA enhances the antitumor efficacy of intratumoral cisplatin in s.c. grafted rat colon tumors. Anticancer Drugs 2004;15:295-9.
86. Behrens J. Cadherins and catenins: role in signal transduction and tumor progression. Cancer Metastasis Rev 1999;18:15-30.
87. Bongiorno PF, al-Kasspooles M, Lee SW, et al. E-cadherin expression in primary and metastatic thoracic neoplasms and in Barrett's oesophagus. Br J Cancer 1995;71:166-72.
88. Tomita K, van Bokhoven A, van Leenders GJ, et al. Cadherin switching in human prostate cancer progression. Cancer Res 2000;60: 3650-4.
89. Patel IS, Madan P, Getsios S, Bertrand MA, MacCalman CD. Cadherin switching in ovarian cancer progression. Int J Cancer 2003;106:172-7.
90. Ahnen DJ, Nakane PK, Brown WR. Ultrastructural localization of carcinoembryonic antigen in normal intestine and colon cancer: abnormal distribution of CEA on the surfaces of colon cancer cells. Cancer 1982;49: 2077-90.
91. Tobioka H, Isomura H, Kokai Y, Sawada N. Polarized distribution of carcinoembryonic antigen is associated with a tight junction molecule in human colorectal adenocarcinoma. J Pathol 2002;198:207-12.
92. Hamada Y, Yamamura M, Hioki K, Yamamoto M, Nagura H, Watanabe K. Immunohistochemical study of carcinoembryonic antigen in patients with colorectal cancer. Correlation with plasma carcinoembryonic antigen levels. Cancer 1985;55:136-41.
93. Delaloye B, Bischof-Delaloye A, Buchegger F, et al. Detection of colorectal carcinoma by emission-computerized tomography after injection of 123I-labeled Fab or F(ab′)2 fragments from monoclonal anti-carcinoembryonic antigen antibodies. J Clin Invest 1986;77:301-11.
94. Mach JP, Buchegger F, Forni M, et al. Immunoscintigraphy for the detection of human carcinoma after injection of radiolabeled monoclonal anti-carcinoembryonic antigen antibodies. Curr Top Microbiol Immunol 1983;104:49-55.
95. Christiansen JJ, Rajasekaran SA, Moy P, et al. Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured epithelial cell line. Prostate 2003;55:9-19.
96. Ballas ZK, Krieg AM, Warren T, et al. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol 2001;167:4878-86.
97. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA 1998;95:652-6.
98. Zeidler R, Reisbach G, Wollenberg B, et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999;163:1246-52.
99. Zeidler R, Mysliwietz J, Csanady M, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000;83:261-6.
100. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-9.
101. Yamamoto S, Yamamoto T, Shimada S, et al. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol 1992;36:983-97.
102. Van Ojik HH, Bevaart L, Dahle CE, et al. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res 2003;63:5595-600.
103. Trauth BC, Klas C, Peters AM, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301-5.
104. Ishizuka H, Watanabe M, Kubota T, Matsuzaki SW, Otani Y, Kitajima M. Antitumor activity of murine monoclonal antibody NCC-ST-421 on human cancer cells by inducing apoptosis. Anticancer Res 1998; 18:2513-8.
105. Fitzpatrick VD, Pisacane PI, Vandlen RL, Sliwkowski MX. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4. FEBS Lett 1998;431:102-6.
106. Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2: 127-37.
107. Estey EH, Giles FJ, Baran M, et al. Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002;99:4222-4.
108. Ballangrud AM, Yang WH, Chariton DE, et al. Response of LNCaP spheroids after treatment with an α-particle emitter (213Bi -labeled antiprostate-specific membrane antigen antibody (J591). Cancer Res 2001; 61:2008-14.
109. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-63.